150-450 mg PO q6-8h
600-900 mg IV q8h
20-30 mg/kg/24h PO divided q6-8h
Maximum: 1.8 g/24h
25-40 mg/kg/24h IV divided q6-8h
Maximum: 900 mg/dose
Anaerobic infections above the diaphragm, especially dental infection.
Gram positive skin and soft tissue infections including necrotizing fasciitis as an adjunctive agent to a beta lactam for reducing toxin production.
Skin and soft tissue infections involving susceptible MRSA.
Susceptible infections and surgical prophylaxis in setting of IgE mediated beta-lactam allergy.
For decreasing toxin production in toxic shock syndrome.
Diarrhea -if severe diarrhea, consider C.diff infection
Allergy (immediate & delayed)
GI upset, diarrhea, pseudomembranous colitis
Abnormal liver enzymes
Concentration: 15 mg/mL
Taste: less palatable, unpleasant taste
Not all strengths of oral liquids are listed nor are available on IWK formulary
150 mg capsule
Tablets and capsules are preferred especially over an unpleasant tasting liquid.
Not all strengths of oral tablets/capsules are listed and they are not all available on the IWK formulary.
Some preparations of Clindamycin injection contain benzyl alcohol, which has caused gasping syndrome in neonates.
Antimicrobial class: Lincosamide
Average serum half life:
Premature neonates: 8.7 hours
Full term neonates: 3.6 hours.
Infants 1 month to 1 year: 3 hours.
Children and Adults: 2-3 hours
Route of Elimination: Mostly hepatic metabolism. 10% of an oral dose excreted in urine and 3.6% excreted in feces as active drug and metabolites.